RINVOQ Drug Patent Profile
✉ Email this page to a colleague
When do Rinvoq patents expire, and when can generic versions of Rinvoq launch?
Rinvoq is a drug marketed by Abbvie and is included in two NDAs. There are forty patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and eighty-eight patent family members in forty-one countries.
The generic ingredient in RINVOQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib profile page.
DrugPatentWatch® Generic Entry Outlook for Rinvoq
Rinvoq was eligible for patent challenges on August 16, 2023.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 17, 2036. This may change due to patent challenges or generic licensing.
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RINVOQ?
- What are the global sales for RINVOQ?
- What is Average Wholesale Price for RINVOQ?
Summary for RINVOQ
International Patents: | 188 |
US Patents: | 39 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 46 |
Clinical Trials: | 39 |
Patent Applications: | 202 |
Drug Prices: | Drug price information for RINVOQ |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RINVOQ |
What excipients (inactive ingredients) are in RINVOQ? | RINVOQ excipients list |
DailyMed Link: | RINVOQ at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RINVOQ
Generic Entry Date for RINVOQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, EXTENDED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for RINVOQ
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Berinstein, Jeffrey | Phase 4 |
The Ottawa Hospital | Phase 4 |
Ottawa Hospital Research Institute | Phase 4 |
Pharmacology for RINVOQ
Drug Class | Janus Kinase Inhibitor |
Mechanism of Action | Janus Kinase Inhibitors |
Paragraph IV (Patent) Challenges for RINVOQ
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
RINVOQ | Extended-release Tablets | upadacitinib | 45 mg | 211675 | 3 | 2023-08-16 |
US Patents and Regulatory Information for RINVOQ
RINVOQ is protected by fifty-three US patents and nine FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of RINVOQ is ⤷ Subscribe.
This potential generic entry date is based on patent 9,951,080.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | No | 9,963,459 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | No | 11,198,697 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-002 | Jan 14, 2022 | RX | Yes | No | 11,661,425 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-003 | Mar 16, 2022 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-003 | Mar 16, 2022 | RX | Yes | Yes | 11,607,411 | ⤷ Subscribe | ⤷ Subscribe | ||||
Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | 11,661,425 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for RINVOQ
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
AbbVie Deutschland GmbH & Co. KG | Rinvoq | upadacitinib | EMEA/H/C/004760 Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. |
Authorised | no | no | no | 2019-12-16 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for RINVOQ
When does loss-of-exclusivity occur for RINVOQ?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 16340167
Patent: Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Estimated Expiration: ⤷ Subscribe
Patent: 20359635
Patent: Treating spondyloarthritic and psoriatic conditions with upadacitinib
Estimated Expiration: ⤷ Subscribe
Patent: 21236570
Patent: Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Estimated Expiration: ⤷ Subscribe
Patent: 23251492
Patent: Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Estimated Expiration: ⤷ Subscribe
Brazil
Patent: 2018007677
Patent: processos para a preparação de (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)pirrolidina-1-carboxamida e suas formas em estado sólido
Estimated Expiration: ⤷ Subscribe
Patent: 2022005765
Patent: Tratamento contra afecções espondiloartríticas e psoriáticas com upadacitinib
Estimated Expiration: ⤷ Subscribe
Patent: 2022024925
Patent: Composição farmacêutica de liberação prolongada compreendendo (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil)pirroli-dina-1-carboxamida
Estimated Expiration: ⤷ Subscribe
Canada
Patent: 02220
Patent: PROCEDE DE PREPARATION DE (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE ET DE SES FORMES A L'ETAT SOLIDE (PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF)
Estimated Expiration: ⤷ Subscribe
Patent: 23260
Patent: HEMIHYDRATE CRISTALLIN DE (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]PYRAZINE-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE ET FORME A L'ETAT SOLIDE (CRYSTALLINE HEMIHYDRATE OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORM THEREOF)
Estimated Expiration: ⤷ Subscribe
Patent: 56170
Patent: TRAITEMENT DES SPONDYLOPATHIES ET DES AFFECTIONS PSORIASIQUES PAR UPADACITINIB (TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIB)
Estimated Expiration: ⤷ Subscribe
China
Patent: 8368121
Patent: 制备(3S,4R)-3-乙基-4-(3H-咪唑并[1,2-a]吡咯并[2,3-e]吡嗪-8-基)-N-(2,2,2-三氟乙基)吡咯烷-1-甲酰胺及其固态形式的方法 (PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF)
Estimated Expiration: ⤷ Subscribe
Patent: 4929227
Patent: 用乌帕替尼治疗脊柱关节炎和银屑病 (Treatment of spinal arthritis and psoriasis with upatinib)
Estimated Expiration: ⤷ Subscribe
Patent: 6270645
Patent: 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 (Method for preparing imidazo [1, 2-a] pyrrolo [2, 3-e] pyrazine compound and solid-state form thereof)
Estimated Expiration: ⤷ Subscribe
Patent: 6270646
Patent: 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 (Method for preparing imidazo [1, 2-a] pyrrolo [2, 3-e] pyrazine compound and solid-state form thereof)
Estimated Expiration: ⤷ Subscribe
Patent: 6284011
Patent: 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 (Method for preparing imidazo [1, 2-a] pyrrolo [2, 3-e] pyrazine compound and solid-state form thereof)
Estimated Expiration: ⤷ Subscribe
European Patent Office
Patent: 62455
Patent: PROCÉDÉ DE PRÉPARATION DE (3S,4R)-3-ÉTHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROÉTHYL)PYRROLIDINE-1-CARBOXAMIDE ET DE SES FORMES À L'ÉTAT SOLIDE (PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF)
Estimated Expiration: ⤷ Subscribe
Patent: 37686
Patent: TRAITEMENT DES SPONDYLOPATHIES ET DES AFFECTIONS PSORIASIQUES PAR UPADACITINIB (TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIB)
Estimated Expiration: ⤷ Subscribe
Patent: 19503
Patent: L-MALEATE SOUS FORME CRYSTALLINE DE (3S,4R)-3-ÉTHYL-4-(3H-IMIDAZO[1,2-A!PYRROLO[2,3-E!PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROÉTHYL)PYRROLIDINE-1-CARBOXAMIDE (CRYTALLINE L-MALEATE OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE)
Estimated Expiration: ⤷ Subscribe
Hong Kong
Patent: 63380
Patent: 製備(3S,4R)-3-乙基-4-(3H-咪唑並[1,2-A]吡咯並[2,3-E]吡嗪-8-基)-N-(2,2,2-三氟乙基)吡咯烷-1-甲醯胺及其固態形式的方法 (PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2- A]PYRROLO[2,3-E]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF)
Estimated Expiration: ⤷ Subscribe
Israel
Patent: 8654
Patent: תהליכים להכנת (3s,4r)-3-אתיל-4-(3h- אימידיאזו[1,2-a]פירולו[2, 3-e]-פיראזין-8-יל)-n-(2,2,2-טריפלורואתיל)פירולידין-1-קרבוקאמיד וצורות במצב מוצק שלהם (Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof)
Estimated Expiration: ⤷ Subscribe
Patent: 3531
Patent: תהליכים להכנת (3s,4r)-3-אתיל-4-(3h- אימידיאזו[1,2-a]פירולו[2, 3-e]-פיראזין-8-יל)-n-(2,2,2-טריפלורואתיל)פירולידין-1-קרבוקאמיד וצורות במצב מוצק שלהם (Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof)
Estimated Expiration: ⤷ Subscribe
Japan
Patent: 70775
Estimated Expiration: ⤷ Subscribe
Patent: 58317
Estimated Expiration: ⤷ Subscribe
Patent: 19501865
Patent: (3S,4R)−3−エチル−4−(3H−イミダゾ[1,2−a]ピロロ[2,3−e]−ピラジン−8−イル)−N−(2,2,2−トリフルオロエチル)ピロリジン−1−カルボキサミドおよびそれの固体型の製造方法
Estimated Expiration: ⤷ Subscribe
Patent: 21020902
Patent: (3S,4R)−3−エチル−4−(3H−イミダゾ[1,2−a]ピロロ[2,3−e]−ピラジン−8−イル)−N−(2,2,2−トリフルオロエチル)ピロリジン−1−カルボキサミドおよびそれの固体型の製造方法 (PROCESSES FOR PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF)
Estimated Expiration: ⤷ Subscribe
Patent: 22107001
Patent: (3S,4R)-3-エチル-4-(3H-イミダゾ[1,2-a]ピロロ[2,3-e]-ピラジン-8-イル)-N-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびそれの固体型の製造方法
Estimated Expiration: ⤷ Subscribe
Patent: 22549379
Patent: ウパダシチニブによる脊椎関節炎及び乾癬状態の治療
Estimated Expiration: ⤷ Subscribe
Patent: 23113917
Patent: (3S,4R)-3-エチル-4-(3H-イミダゾ[1,2-a]ピロロ[2,3-e]-ピラジン-8-イル)-N-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびそれの固体型の製造方法 (METHODS FOR PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF)
Estimated Expiration: ⤷ Subscribe
Mexico
Patent: 18004605
Patent: PROCESOS PARA LA PREPARACION DE (3S,4R)-3-ETIL-4-(3H-IMIDAZO-[1,2- A]-PIRROLO-[2,3-E]-PIRAZIN-8-IL)-N-(2,2,2-TRIFLUOROETIL)-PIRROLID IN-1-CARBOXAMIDA Y FORMAS EN ESTADO SOLIDO DE LA MISMA. (PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1, 2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLI DINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF.)
Estimated Expiration: ⤷ Subscribe
Patent: 21013812
Patent: PROCESOS PARA LA PREPARACION DE (3S,4R)-3-ETIL-4-(3H-IMIDAZO[1,2-A ]PIRROLO[2,3-E]-PIRAZIN-8-IL)-N-(2,2,2-TRIFLUOROETIL) PIRROLIDIN-1-CARBOXAMIDA Y FORMAS EN ESTADO SOLIDO DE LA MISMA. (PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1, 2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLI DINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF.)
Estimated Expiration: ⤷ Subscribe
Patent: 22003872
Patent: TRATAMIENTO DE AFECCIONES ESPONDILOARTRÍTICAS Y PSORIÁSICAS CON UPADACITINIB. (TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIB.)
Estimated Expiration: ⤷ Subscribe
Russian Federation
Patent: 18117889
Patent: СПОСОБЫ ПОЛУЧЕНИЯ (3S,4R)-3-ЭТИЛ-4-(3H-ИМИДАЗО[1,2-a]ПИРРОЛО[2,3-e]-ПИРАЗИН-8-ИЛ)-N-(2,2,2-ТРИФТОРЭТИЛ)ПИРРОЛИДИН-1-КАРБОКСАМИДА И ЕГО ТВЕРДОФАЗНЫХ ФОРМ
Estimated Expiration: ⤷ Subscribe
Singapore
Patent: 201913986Y
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Subscribe
Patent: 201913987U
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Subscribe
Patent: 201913989Q
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Subscribe
Patent: 201913990R
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Subscribe
Patent: 201913993Q
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Subscribe
Patent: 201913997W
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Subscribe
Patent: 201913999P
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Subscribe
Patent: 201802990R
Patent: PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Estimated Expiration: ⤷ Subscribe
South Korea
Patent: 180081523
Estimated Expiration: ⤷ Subscribe
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering RINVOQ around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Cyprus | 1117165 | ⤷ Subscribe | |
Denmark | 2299821 | ⤷ Subscribe | |
Japan | 2024073591 | (3S,4R)-3-エチル-4-(3H-イミダゾ[1,2-a]ピロロ[2,3-e]-ピラジン-8-イル)-N-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびそれの固体型の製造方法 (PROCESSES FOR PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF) | ⤷ Subscribe |
Mexico | 2012006311 | NUEVOS COMPUESTOS TRICICLICOS. (NOVEL TRICYCLIC COMPOUNDS.) | ⤷ Subscribe |
Peru | 20121336 | NUEVOS COMPUESTOS TRICICLICOS | ⤷ Subscribe |
Russian Federation | 2010153582 | НОВЫЕ ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ | ⤷ Subscribe |
Taiwan | 201612182 | Novel tricyclic compounds | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RINVOQ
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2506716 | 12/2020 | Austria | ⤷ Subscribe | PRODUCT NAME: UPADACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1404 (MITTEILUNG) 20191218 |
2506716 | 2020/010 | Ireland | ⤷ Subscribe | PRODUCT NAME: UPADACITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT REGISTRATION NO/DATE: EU/1/19/1404 20191218; FIRST REGISTRATION NO/DATE: EU/1/19/1404 18/12/2019 (11/11/2020) |
2506716 | 723 | Finland | ⤷ Subscribe | |
2506716 | CA 2020 00011 | Denmark | ⤷ Subscribe | PRODUCT NAME: UPADACITINIB; REG. NO/DATE: EU/1/19/1404 20191218 |
2506716 | CR 2020 00011 | Denmark | ⤷ Subscribe | PRODUCT NAME: UPADACITINIB; REG. NO/DATE: EU/1/19/1404 20191218 |
2506716 | LUC00149 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: UPADACITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218 |
2506716 | PA2020505,C2506716 | Lithuania | ⤷ Subscribe | PRODUCT NAME: UPADACITINIBAS; REGISTRATION NO/DATE: EU/1/19/1404 20191216 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
RINVOQ Market Analysis and Financial Projection
More… ↓